Expression of telomeric-repeat binding factor-1 and telomeric-repeat binding factor-2 mRNA and protein in the peripheral blood mononuclear cells of patients with systemic lupus erythematosus

• DOI: 10.3760/cma.j.issn.1007-7480.2016.09.005
• Publication Date: 2016-09-15
• Authors: Mengyun Zhang; Yufeng Qing; Shu-Yue Pan; Mengjun Pu; Qibin Yang; Cuipin Huang

Objective To investigate the mRNA and protein expression levels of telomeric-repeat binding factor-1 (TRF1) TRF2 in peripheral blood mononuclear cells (PBMCs) patients with systemic lupus erythematosus (SLE), relations between these gene clinical data SLE were explored.

Methods According to disease activity, divided into active group (40 cases) stable (67 cases). These also grouped as renal damage (46 damage-free (61 based on their conditions. Healthy individuals (41 included control. Real-time quantitative polymerase chain reaction (RT-qPCR) was employed study TRF1 TRF2. The measured by Western Blot (WB). Independent-Samples t test or one-way analysis variance (ANOVA) conjunction Least-Significant Difference method (LSD method) wasperformed if normal distributions; otherwise, Kruskal-Wallis applied. Spearman's correlation used for statistical analysis.

Results The inthe PBMCs (TRF1: 0.003 1±0.003 3; TRF2: 0.010 5±0.064 8) 0.002 3 ± 6; 0.004 3) significantly increased compared 0.001 2±0.001 1; 2±0.008 6), 3±0.001 8; 4 0.007 2) healthy 2 0; 7) respectively (P<0.05). In patients, correlated erythrocyte sedimentation rate (r=0.365, P<0.05); SLEDAI score (r=0.270, P<0.05) , (r=0.304, P<0.05), creatinine (r=0.258, 24-hour urinary (r=0.344, P<0.05).

Conclusion Altered might be involved pathogenesis Systemic erythematosus. positive score, suggest that usedas a biomarker activity SLE.

Key words: Lupus erythematosus, systemic; Lupus nephritis; Telomeric repeat 1; Telomerice